MAGEA4 and liver cancer: Research has found that doxorubicin can promote MAGE-A4 cleavage by activating the proteasome, producing C-terminal fragments with pro-apoptotic activity, thereby enhancing the sensitivity of liver cancer cells to doxorubicin.